At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 43 enrolled
Drug / intervention
Tafluprost 0.0015%drug
Likely dose
Tafluprost 0.0015% 0.015 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulation in Patients With Open-angle Glaucoma or Ocular Hypertension
In Brief
A Phase 3 clinical trial evaluating Tafluprost 0.0015% for Open-Angle Glaucoma and Ocular Hypertension. Completed, enrolled 43 participants across 3 sites in 2 countries.
Detailed Summary
The objective of this study is to investigate the pharmacodynamics (as expressed in intraocular pressure \[IOP\]) of two formulations of tafluprost 0.0015% eyedrops (preserved and unpreserved) in patients with open-angle glaucoma or ocular hypertension. The primary aim of this study is to show that IOP reduction between the two formulations is equivalent at the end of the 4 week treatment period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen-Angle Glaucoma, Ocular Hypertension
CountriesFinland, Germany
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2005
Primary CompletionMar 2006
Study CompletionApr 2006
First PostedJun 2009
TodayJul 2026
First PostedJun 11, 2009
Enrollment StartSep 1, 2005
Primary CompletionMar 1, 2006
Study CompletionApr 1, 2006
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 17.1 years ago
Interventions
Tafluprost 0.0015%drug
Eye drops, 0.015 mg/ml, once daily to affected eye(s)